利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.022 秒)

    BACTERIUM FOR USE AS A PROBIOTIC FOR NUTRITIONAL AND MEDICAL APPLICATIONS
    1.
    发明申请
    BACTERIUM FOR USE AS A PROBIOTIC FOR NUTRITIONAL AND MEDICAL APPLICATIONS 审中-公开

    公开(公告)号：US20180271918A1

    公开(公告)日：2018-09-27

    申请号：US15906988

    申请日：2018-02-27

    申请人： 4D Pharma Research Limited

    发明人： Denise KELLY ,  Imke MULDER

    IPC分类号： A61K35/741 ,  A61K35/74 ,  A23K10/18 ,  A23L33/135 ,  A61K9/00

    摘要： A first aspect of the invention relates to the bacterial species Roseburia hominis for use in: regulating the immune system of a subject treating an immune disorder; treating an intestinal disorder; improving intestinal microbiota; regulating the innate immune system of a subject; regulating the adaptive immune system of a subject; regulating appetite in a subject; promoting Tregs and immune tolerance; promoting gut health in a subject; and/or maintaining immune homeostasis in a subject. Further aspects of the invention relate to compositions comprising Roseburia hominis.

    PIRIN POLYPEPTIDE AND IMMUNE MODULATION
    2.
    发明申请
    PIRIN POLYPEPTIDE AND IMMUNE MODULATION 有权

    公开(公告)号：US20210260156A1

    公开(公告)日：2021-08-26

    申请号：US17193348

    申请日：2021-03-05

    申请人： 4D PHARMA RESEARCH LIMITED

    发明人： Denise KELLY

    IPC分类号： A61K38/16 ,  A23L33/135 ,  A23L33/17 ,  A61K39/02 ,  A61K35/741 ,  A23L33/18

    摘要： The present invention relates to polypeptide HP, or a polynucleotide sequence encoding polypeptide HP, or a host cell comprising said polynucleotide sequence, or a host cell comprising an expression vector comprising said polynucleotide sequence, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof.

    LACTIC ACID BACTERIAL STRAINS
    3.
    发明申请
    LACTIC ACID BACTERIAL STRAINS 审中-公开

    公开(公告)号：US20190216865A1

    公开(公告)日：2019-07-18

    申请号：US16206250

    申请日：2018-11-30

    申请人： 4D Pharma Research Limited

    发明人： Denise KELLY

    IPC分类号： A61K35/747 ,  A23L33/135 ,  A23K10/18 ,  C12R1/25 ,  C12R1/225 ,  C12R1/23 ,  C12N1/20

    CPC分类号： A61K35/747 ,  A23K10/18 ,  A23L33/135 ,  A23V2002/00 ,  C12N1/20 ,  C12R1/225 ,  C12R1/23 ,  C12R1/25 ,  Y02A50/473 ,  Y02A50/481

    摘要： A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli; (ii) the ability to exhibit antimicrobial activity against S. enteritidis; (iii) the ability to suppress inflammation in IPEC cells induced by 12-0-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis; (v) the ability to block the attachment or invasion of IPEC cells by E. coli; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes. Further aspects of the invention relate to compositions comprising said bacterial strains, and therapeutic uses of said bacterial strains.

    PIRIN POLYPEPTIDE AND IMMUNE MODULATION
    6.
    发明申请
    PIRIN POLYPEPTIDE AND IMMUNE MODULATION 审中-公开

    公开(公告)号：US20200164027A1

    公开(公告)日：2020-05-28

    申请号：US16560381

    申请日：2019-09-04

    申请人： 4D PHARMA RESEARCH LIMITED

    发明人： Denise KELLY

    IPC分类号： A61K38/16 ,  A23L33/18 ,  A23L33/17 ,  A23L33/135

    摘要： The present invention relates to polypeptide HP, or a polynucleotide sequence encoding polypeptide HP, or a host cell comprising said polynucleotide sequence, or a host cell comprising an expression vector comprising said polynucleotide sequence, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof.

    PIRIN POLYPEPTIDE AND IMMUNE MODULATION
    7.
    发明申请
    PIRIN POLYPEPTIDE AND IMMUNE MODULATION 审中-公开

    公开(公告)号：US20170326202A1

    公开(公告)日：2017-11-16

    申请号：US15631952

    申请日：2017-06-23

    申请人： 4D PHARMA RESEARCH LIMITED

    发明人： Denise KELLY

    IPC分类号： A61K38/16 ,  A23L33/18 ,  A23L33/135

    CPC分类号： A61K38/164 ,  A23L33/135 ,  A23L33/17 ,  A23L33/18 ,  A23V2002/00

    摘要： The present invention relates to polypeptide HP, or a polynucleotide sequence encoding polypeptide HP, or a host cell comprising said polynucleotide sequence, or a host cell comprising an expression vector comprising said polynucleotide sequence, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof.